Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Breast 2Sarcoma 1Genitourinary 1Gastrointestinal 1Classical hematology 1

Conditions

Breast Neoplasms 29Triple Negative Breast Neoplasms 13Ovarian Neoplasms 5Prostatic Neoplasms 3Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Ovarian Epithelial 2Triple Negative Metastatic Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Recurrence 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Pathologic Complete Response 1Mesothelioma 1Hemangiosarcoma 1Gastrointestinal Neoplasms 1Fanconi Anemia, Complementation Group D1 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Breast Adenocarcinoma 1Advanced Ovarian Cancer 1Advanced Breast Cancer 1

Interventions

Paclitaxel 10pembrolizumab 9Cyclophosphamide 9Flow Cytometry 7sargramostim 6Therapeutics 6Taxes 5Polymerase Chain Reaction 5Immunoenzyme Techniques 5Docetaxel 5Carboplatin 5aldesleukin 4Psychiatric Rehabilitation 4Fulvestrant 4Filgrastim 4ribociclib 3Trastuzumab 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Mass Spectrometry 3Interleukin-12 Subunit p35 3Immunologic Techniques 3Immunohistochemistry 3Gene Expression Profiling 3Amplified Fragment Length Polymorphism Analysis 3Amifostine 3talazoparib 2spartalizumab 2sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × talazoparib × Breast × Clear all
NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Pfizer

Phase 1/2 Terminated
223 enrolled 50 charts
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Pfizer

Phase 1 Completed
113 enrolled 39 charts
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡